# Apremilast for Erythema Multiforme

> **NCT05875714** · PHASE2 · COMPLETED · sponsor: **Robert Micheletti** · enrollment: 8 (actual)

## Conditions studied

- Erythema Multiforme

## Interventions

- **DRUG:** Apremilast

## Key facts

- **NCT ID:** NCT05875714
- **Lead sponsor:** Robert Micheletti
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-13
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05875714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05875714, "Apremilast for Erythema Multiforme". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05875714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*